Available online at : (accessed on 10 December 2017)
As individuals vary, so may the results from using this product
In the gastrointestinal tract, BPC-157 demonstrates gastric cytoprotection in animal models, reducing ulcer formation and accelerating mucosal healing at doses consistent with tendon repair studies
Last reviewed: May 12, 2026 Last updated: May 12, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
With obesity affecting roughly 42 percent of American adults, the potential user base for weight loss peptides was enormous